PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | perso | ns are required to resp | ond to a collection of information | on unless it displays a valid OMB control number |
|-------|---|-------|-------------------------|------------------------------------|--|
| THAU | Substitute for form 1449A/PTO | | | Co | mplete if Known |
| | | | | Application Number | 09/944,326 |
| | INFORMATION DISCLOSURE STATEMENT BY APPLICANT | SURE | Filing Date | 8/30/2001 | |
| | STATEMENT BY AP | PLI | CANT | First Named Inventor | Gleave et al. |
| | |) | Art Unit | 1635 | |
| | | | | Examiner Name | K. A. Lacourciere |
| Sheet | 1 | of | 3 | Attorney Docket Number | UBC.P-020-2 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|-------------------------------|--------------------------------|--|---|--|--|
| Examiner Initials* | Cite | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where | | |
| | No.' | Number-Kind Code ² | MINITED TITLE | Applicant of Cited Document | Relevant Passages or Relevant Figures Appear | | |
| TY | | US-6,172,216 B1 | 1/9/2001 | Bennett et al. | | | |
| | | US: | | | | | |
| | | US- | | | | | |
| | <u> </u> | US∙ | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | <u> </u> | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |
| | | US- | | | | | |

| | FOREIGN PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|---|--|
| Examiner Initials* | Cite No.1 | Foreign Patent Document Country Code* ·Number*- Kind Code* (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | ۳ | |
| | | WO 00/49937 | 8/31/2000 | The University of British Columbia | | Г | |
| | ` | WO 02/22635 A1 | 3/21/2002 | ISIS Pharmaceuticals, Inc. | | | |
| | | WO 03/062421 A1 | 7/31/2003 | The University of British Columbia | | | |
| | | WO 03/072591 A1 | 9/4/2003 | The University of British Columbia | | | |
| | | | | | | | |
| | 5 | | | | | - | |

| Examiner Signature | 101 | room | Willemora | Date Considered | 5/14/05 | |
|--------------------|-----|------|-----------|--------------------|---------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.upsto.gov/or/MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ° For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ° Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ° Applicant is to place a check mark here if English language Translation is attached.

language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

~

and select option 2.

W. . # .

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number

| IMAUS dostitute for | form 1449B/PTO | | | | Complete if Known |
|---------------------|---|------------|----------------------|------------------------|-------------------|
| 111505 | MATION DI | 001.00 | | Application Number | 09/944,326 |
| INFOH | NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Application Number 09/944,326 Filing Date 8/30/2001 First Named Inventor Gleave et al. Art Unit 1635 Examiner Name K. A. Lacourclere | 8/30/2001 | | | |
| STATE | | ANT | First Named Inventor | Gleave et al. | |
| | | 1635 | | | |
| (6 | Use <u>as many sheets</u> as | necessary) | | Examiner Name | K. A. Lacourciere |
| Sheet | 2 | of | 3 | Attorney Docket Number | UBC.P-020-2 |

| | | NON PATENT LITERATURE DOCUMENTS | | | | |
|------------|---|---|--|--|--|--|
| 1-4:-1-+ I | | Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published | | | | |
| Ťν | , | GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2 to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, Page(s) 39-49, Volume 58, XP-002262320 | | | | |
| ` | , | GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, Page(s) 79-92, Volume 21, XP-001147871 | | | | |
| ; | | GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Number 2, XP 009021411 | | | | |
| | , | GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, Page(s) 209-221, Volume 4 | | | | |
| : | , | JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, Page(s) 427-431, Volume 34, XP002262319 | | | | |
| | ` | MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both In Vitro and in Vivo, Clinical Cancer Research, 2000, Page(s) 1655-1663, Volume 6, Number 5, Publisher: The American Association for Cancer Research, US, XP000960694 | | | | |
| | • | MIYAKE ET AL., Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model, Clinical Cancer Research, 2001, Page(s) 4245-4252, Volume 7 | | | | |
| · | | MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001, Page(s) 337-349, Volume 8, Number 7, XP002262321 | | | | |
| | • | ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, Page(s) 633-645, Volume 27, Number 7, XP001002844 | | | | |
| | • | WILSON ET AL., Clusterin is a secreted mammallan chaperone, TIBS, 2000, Page(s) 95-98, Volume 25, XP 4202536A | | | | |
| _ 1 | , | WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, Page(s) 917-925, Volume 227, Number 3, XP 001146404 | | | | |

| Examiner Signature | (V) | haan | Vilamore | Date Considered | 5/16/05 |
|-----------------------|-----|------|----------|--------------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

ays a valid OMB control number. Substitute for form 1449B/PTO Complete if Known Application Number 09/944,326 INFORMATION DISCLOSURE Filing Date 8/30/2001 First Named Inventor Gleave et al. STATEMENT BY APPLICANT Art Unit 1635 Examiner Name K. A. Lacourciere (Use as many sheets as necessary) Sheet Attorney Docket Number UBC.P-020-2

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|---|---|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| 14 | ` | ZANGEMEISTER-WITTKE ET AL., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells, Clinical Cancer Research, 2000, Page(s) 2547-2555, Volume 6, XP-002241562 | |
| | • | ZELLWEGER ET AL., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2'O-(2-Methoxy)Ethyl Chemistry, The Journal of Pharmacology and Experimental, 2001, Page(s) 934-940, Volume 298, Number 3, XP-002262318 | |
| | , | ZELLWEGER ET AL., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the antiapoptotic Gene Clusterin, Neoplasia, 2001, Page(s) 360-367, Volume 3, Number 4 | |
| | | | |
| | | | |
| | | | |
| | - | | |
| | | • | |
| | | | _ |
| | | | |
| | | | |
| | | | |
| xaminer Signature | V | Date Considered 5/16/05 | |

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. PAD Stitute for form 1449A/PTO Complete if Known Application Number 09/944,326 INFORMATION DISCLOSURE Filing Date 8/30/2001 First Named Inventor STATEMENT BY APPLICANT Gleave et al.

Art Unit (Use as many sheets as necessary) 1635 **Examiner Name** Tracy Ann Vivlemore Sheet of 1 2 Attorney Docket Number UBC.P-020-2

| | | | U.S. PATENT (| DOCUMENTS | |
|-------------|--|-------------------------------|---|--|---|
| | Cite | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant |
| | No.1 | Number-Kind Code ² | 111111111111111111111111111111111111111 | Applicant of oked bocument | Figures Appear |
| | | US-5,046,042 | 07-08-1997 | Stinshoorsb et al. | |
| | | US-5,929:040 | 07-27-1999 | Wenner et al- | |
| ****** | <u> </u> | U8 | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | <u> </u> | US- | | | |
| | <u> </u> | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | 4 | <u> </u> | |
| | | us- | | | |

| | | FORE | IGN PATENT DOCU | MENTS | ····· | |
|-----------------------|--------------------------|--|--------------------------------|--|---|----|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code* -Number* - Kind Code* (il known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | ۳⁰ |
| | ļ | | | | | |
| | | | | | | |
| | | | | | | |
| | <u> </u> | | | | | |
| | | | | | | |
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicants unique citation designation number (optional). See Kinds Codes of US PTO Patent Documents at <a href="https://www.upsto.gov/effect/bell/wwww.upsto.gov/effect/bell/www.upsto.gov/effect/bell/www.upsto.gov/effect/bell/ patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

COMP CO

Date

Examiner

Signature

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Bacework Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

| DA DELLA | INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete If Known | | | | |
|----------|--|--------|-------------------|------------------------|---------------------|--|--|
| | | | | Application Number | 09/944,326 | | |
| INF | ORMATION DISC | LOS | UKE | Filing Date | 8/30/2001 | | |
| ST | ATEMENT BY APP | PLIC | ANT | First Named Inventor | Gleave et al. | | |
| | | | | Art Unit | 1635 | | |
| | (Use as many sheets as nece | ssary) | | Examiner Name | Tracy Ann Vivlemore | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | UBC.P-020-2 | | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|---|----|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| | | AGRAWAL ET AL., Antisense Therapeutius is it as simple as complementary base recognition, Molecular Medicine Today, 2000, Page(e) 72-81, Volume 6, Publisher: Elsevier Science Ltd. | |
| | + | ANDREA D. BRANCH, A good antisense melecule is hard to fing JHSS, 1998, Page(s) 45-50, Publisher: Elsovier Science-Ltd. | |
| - | | CROOKE ET AL., Basic Principles of Antisonse Therapeutics, Antisense Research and Application, 2004, Page(s) 1 50, Publisher Springer | |
| | | SEN ET AL., Suppression of Sene Expression by Targeted Disruption of Messenger RNA. Available Options and Current Strategies, Stem Cells 2000, 2000, Page(s) 397 319, Volume 18. | |
| | | OPACINSKA ET AL., Nucleic-acid therapoutics: Basic principles and recent applications, Nature Reviews, 2000, Page(s) 503-514, Volume 1 | |
| | | · | ļ |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | _ |

Examiner Date

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Complete the Complete of Patents P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.